Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease
SEMINARS IN RADIATION ONCOLOGY, cilt.31, sa.3, ss.217-226, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 31 Sayı: 3
- Basım Tarihi: 2021
- Doi Numarası: 10.1016/j.semradonc.2021.02.005
- Dergi Adı: SEMINARS IN RADIATION ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.217-226
- Hacettepe Üniversitesi Adresli: Evet
Özet
Metastatic cancer is inherently heterogeneous, and patients with metastatic disease can experience vastly different oncologic outcomes depending on several patient-and disease specific characteristics. Designing trials for such a diverse population is challenging yet necessary to improve treatment outcomes for metastatic-previously thought to be incurable-disease. Here we review core considerations for designing and conducting clinical trials involving radiation therapy and immunotherapy for patients with metastatic cancer. Semin Radiat Oncol 31:217-226 Published by Elsevier Inc.